@article{adcde77a6c8549b4ab997a367dd8e7a8,
title = "Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus",
abstract = "Preclinical development of and research on potential Middle East respiratory syndrome coronavirus (MERS-CoV) medical countermeasures remain preliminary; advancements are needed before most countermeasures are ready to be tested in human clinical trials. Research priorities include standardization of animal models and virus stocks for studying disease pathogenesis and efficacy of medical countermeasures; development of MERS-CoV diagnostics; improved access to nonhuman primates to support preclinical research; studies to better understand and control MERS-CoV disease, including vaccination studies in camels; and development of a standardized clinical trial protocol. Partnering with clinical trial networks in affected countries to evaluate safety and efficacy of investigational therapeutics will strengthen efforts to identify successful medical countermeasures.",
author = "Uyeki, {Timothy M.} and Erlandson, {Karl J.} and George Korch and Michael O'Hara and Michael Wathen and Jean Hu-Primmer and Sally Hojvat and Stemmy, {Erik J.} and Armen Donabedian",
note = "Funding Information: We thank John Beigel, Wendy Carter, David Cho, Su-Young Choi, Eric Donaldson, Heinz Feldmann, Barney Graham, Lisa Hensley, Cynthia Kelley, Peter Miele, Vincent Munster, David Spiro, Kanta Subbarao, and Melissa Willis for participating in foundational discussions and for help assessing potential therapeutic drugs and methods; vaccines under development or investigation; timelines for animal studies; scale-up of medical countermeasures; when human trials are to be started; regulatory issues for investigational new drug (IND) and emergency use authorization (EUA) applications, and clinical studies; and safety issues and prioritization for clinical trials. We also thank Dean Erdman for insightful discussions on MERS-CoV diagnostic assay development, Rick Bright, Tom Dreier, and Byron Rippke for helpful commentary, and Thuy Phan for organizational assistance. Dr. Uyeki is the Chief Medical Officer for the Influenza Division, National Center for Immunization and Respiratory Diseases, CDC. His research interests are in the epidemiology and clinical management of influenza and emerging infectious diseases. Publisher Copyright: {\textcopyright} 2016 Centers for Disease Control and Prevention (CDC). All rights reserved.",
year = "2016",
month = jul,
doi = "10.3201/EID2207.160022",
language = "English (US)",
volume = "22",
pages = "E1--E11",
journal = "Emerging infectious diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention (CDC)",
number = "7",
}